JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Edes, Kornelia ^a   Cassidy, Pamela ^a,b,c   Shami, Paul J ^b   Moos, Philip J ^c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2,4 DINITROPHENYL) 1 [(4 ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; 4 HYDROXYNONENAL; CASPASE; HYDROGEN PEROXIDE; NITRIC OXIDE DONOR; PRODRUG; SMALL INTERFERING RNA; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG; AZO COMPOUND; O(2) (2,4 DINITROPHENYL) 1 ((4 ETHOXYCARBONYL)PIPERAZIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; O(2)-(2,4-DINITROPHENYL) 1-((4-ETHOXYCARBONYL)PIPERAZIN-1-YL)DIAZEN-1-IUM-1,2-DIOLATE; PIPERAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; ATTENUATION; CANCER CELL CULTURE; CELL GROWTH; CELL KINETICS; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; OXIDATION REDUCTION STATE; PROTEIN EXPRESSION; SELENIUM DEFICIENCY; COLORECTAL TUMOR; ENZYMOLOGY; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

AZO COMPOUNDS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE KNOCKDOWN TECHNIQUES; HUMANS; NITRIC OXIDE DONORS; PIPERAZINES; PRODRUGS; THIOREDOXIN REDUCTASE 1;

EID: 77649290545     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008786     Document Type: Article

References (56)

1. Rundlof AK, Arner ES (2004) Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal 6: 41-52.
2. Spyrou G, Holmgren A (1996) Deoxyribonucleoside triphosphate pools and growth of glutathione-depleted 3T6 mouse fibroblasts. Biochem Biophys Res Commun 220: 42-46.
3. Spyrou G, Bjornstedt M, Kumar S, Holmgren A (1995) AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione. FEBS Lett 368: 59-63.
4. Hu J, Ma X, Lindner DJ, Karra S, Hofmann ER, et al. (2001) Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the Interferon-Retinoid combination. Oncogene 20: 4235-4248.
5. Huang LE, Arany Z, Livingston DM, Bunn HF (1996) Activation of hypoxiainducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259.
6. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT (1992) Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 20: 3821-3830.
7. Biaglow JE, Miller RA (2005) The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 4: 6-13.
8. Yoo MH, Xu XM, Carlson BA, Patterson AD, Gladyshev VN, et al. (2007) Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS ONE 2: e1112.
9. Bjornstedt M, Hamberg M, Kumar S, Xue J, Holmgren A (1995) Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem 270: 11761-11764.
10. Arner ES, Nordberg J, Holmgren A (1996) Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem Biophys Res Commun 225: 268-274.
11. Nordberg J, Arner ES (2001) Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31: 1287-1312.
12. Moos PJ, Edes K, Cassidy P, Massuda E, Fitzpatrick FA (2003) Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 278: 745-750.
13. Cassidy PB, Edes K, Nelson CC, Parsawar K, Fitzpatrick FA, et al. (2006) Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 27: 2538-2549.
14. Fang J, Holmgren A (2006) Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J Am Chem Soc 128: 1879-1885.
15. Lothrop AP, Ruggles EL, Hondal RJ (2009) No selenium required: reactions catalyzed by mammalian thioredoxin reductase that are independent of a selenocysteine residue. Biochemistry 48: 6213-6223.
16. Anestal K, Prast-Nielsen S, Cenas N, Arner ES (2008) Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS One 3: e1846.
17. Hofmann ER, Boyanapalli M, Lindner DJ, Weihua X, Hassel BA, et al. (1998) Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol 18: 6493-6504.
18. Lamas S, Perez-Sala D, Moncada S (1998) Nitric oxide: from discovery to the clinic. Trends Pharmacol Sci 19: 436-438.
19. Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
20. Moncada S, Higgs EA (2006) The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 147 Suppl 1: S193-201.
21. Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, et al. (2003) JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther 2: 409-417.
22. Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, et al. (2007) JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110: 709-718.
23. Shami PJ, Saavedra JE, Bonifant CL, Chu J, Udupi V, et al. (2006) Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl]-diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem 49: 4356-4366.
24. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS (2005) Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6: 150-166.
25. Stoyanovsky DA, Tyurina YY, Tyurin VA, Anand D, Mandavia DN, et al. (2005) Thioredoxin and lipoic acid catalyze the denitrosation of low molecular weight and protein S-nitrosothiols. J Am Chem Soc 127: 15815-15823.
26. Kim KM, Kim PK, Kwon YG, Bai SK, Nam WD, et al. (2002) Regulation of apoptosis by nitrosative stress. J Biochem Mol Biol 35: 127-133.
27. Benhar M, Forrester MT, Hess DT, Stamler JS (2008) Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320: 1050-1054.
28. Bersani NA, Merwin JR, Lopez NI, Pearson GD, Merrill GF (2002) Protein electrophoretic mobility shift assay to monitor redox state of thioredoxin in cells. Methods Enzymol 347: 317-326.
29. Bleys J, Navas-Acien A, Guallar E (2008) Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 168: 404-410.
30. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281: 13005-13008.
31. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, et al. (2001) Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7: 3087-3091.
32. Shao L, Diccianni MB, Tanaka T, Gribi R, Yu AL, et al. (2001) Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. Cancer Res 61: 7333-7338.
33. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, et al. (2000) Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 31: 475-481.
34. Nilsson J, Soderberg O, Nilsson K, Rosen A (2000) Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. Blood 95: 1420-1426.
35. Bracht K, Liebeke M, Ritter CA, Grunert R, Bednarski PJ (2007) Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. Anticancer Drugs 18: 389-404.
36. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39: 696-703.
37. Ravi D, Das KC (2004) Redox-cycling of anthracyclines by thioredoxin system: increased superoxide generation and DNA damage. Cancer Chemother Pharmacol 54: 449-458.
38. Wang X, Zhang J, Xu T (2007) Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol Appl Pharmacol 218: 88-95.
39. Arivarasu NA, Fatima S, Mahmood R (2007) Effect of cisplatin on brush border membrane enzymes and anti-oxidant system of rat intestine. Life Sci 81: 393-398.
40. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23: 2425-2433.
41. Arner ES, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16: 420-426.
42. Udupi V, Yu M, Malaviya S, Saavedra JE, Shami PJ (2006) JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. Leuk Res 30: 1279-1283.
43. Sun Y, Rigas B (2008) The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 68: 8269-8277.
44. Anestal K, Arner ES (2003) Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278: 15966-15972.
45. Watson WH, Heilman JM, Hughes LL, Spielberger JC (2008) Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem Biophys Res Commun 368: 832-836.
46. Moos PJ, Edes K, Fitzpatrick FA (2000) Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci U S A 97: 9215-9220.
47. Seemann S, Hainaut P (2005) Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene 24: 3853-3863.
48. Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A (2006) Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281: 10691-10697.
49. Amato RJ, Jac J, Hernandez-McClain J (2008) Motexafin Gadolinium for the Treatment of Metastatic Renal Cell Carcinoma: Phase II Study Results. Clin Genitourin Cancer 6: 73-78.
50. William WN Jr, Zinner RG, Karp DD, Oh YW, Glisson BS, et al. (2007) Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol 2: 745-750.
51. Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, et al. (2007) Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69: 831-838.
52. Richards GM, Mehta MP (2007) Motexafin gadolinium in the treatment of brain metastases. Expert Opin Pharmacother 8: 351-359.
53. Rosenberg A, Knox S (2006) Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys 64: 343-354.
54. Saavedra JE, Srinivasan A, Bonifant CL, Chu J, Shanklin AP, et al. (2001) The secondary amine/nitric oxide complex ion R(2)N[N(O)NO](-) as nucleophile and leaving group in S9N)Ar reactions. J Org Chem 66: 3090-3098.
55. May JM, Qu ZC, Nelson DJ (2007) Uptake and reduction of alpha-lipoic acid by human erythrocytes. Clin Biochem 40: 1135-1142.
56. Mullally JE, Moos PJ, Edes K, Fitzpatrick FA (2001) Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 276: 30366-30373.